Praluent Odyssey: Regeneron/Sanofi gun for market breakout with first-ever mortality benefit — and a big price discount
Few drug rivalries have been carried out with more direct, hand-to-hand fighting than the scrap over the PCSK9 market. Marginal as the market is now, the combined forces of Regeneron and Sanofi allied against Amgen have nevertheless punched it out in court and the playing field in the devout belief that billions are at stake. And all three have had to struggle with a payers’ backlash against the two drugs they’re selling.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
